Trial Profile
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NJA-730 in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2021
Price :
$35
*
At a glance
- Drugs NJA 730 (Primary)
- Indications Autoimmune disorders; Graft-versus-host disease
- Focus Adverse reactions; First in man
- Sponsors NapaJen Pharma
- 03 Mar 2021 Status changed from recruiting to completed.
- 24 Feb 2020 A third part (Part 3), included, an extension study, which will include 24 volunteers divided in 4 cohorts.
- 24 Feb 2020 Planned End Date changed from 19 Apr 2019 to 29 May 2020.